

## Twice-rejected Barhemsys finally gets its nod



[Elizabeth Cairns](#)

Following two complete response letters over the past year and a half, and having finally found a reliable supplier for the active ingredient, Acacia Pharma has got Barhemsys over the finish line and on to the US market. The dopamine receptor blocker's approval as a rescue medication for postoperative nausea and vomiting pushed the UK group's stock up 27%, though this has not quite made up for the sharp fall last May when Barhemsys was [rejected a second time](#). Acacia intends to launch the drug with its own direct sales force in the second half of this year. Another approval could be on the way; last month Acacia licensed exclusive US rights to Byfavo from Cosmo Pharmaceuticals, at which point the ultra-short-acting sedative was already filed with the FDA. Assuming Byfavo is approved by its PDUFA date, April 5, Acacia will soon be selling two drugs targeting essentially the same market - anaesthesiologists and hospital pharmacists. According to consensus forecasts from *EvaluatePharma*, both Byfavo and Barhemsys are forecast to sell around \$103m each in the US by 2024.

### Acacia Pharma's share price



Vantage

[More from Evaluate Vantage](#)

Evaluate HQ  
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas  
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC  
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2022 Evaluate Ltd.